Abstract 4842
Background
The incidence of pancreatic cancer (PAC) has continued to rise in recent years. PAC can be divided into head of PAC (HPAC) and body/tail of PAC (BTPAC) by the anatomical location. The patients (pts) with BTPAC are usually diagnosed at relatively advanced stage and had worse survival than those with HPAC. The comparative molecular signatures between different locations in Chinese PAC pts remain unclear.
Methods
154 tumor specimens (HPAC, N = 85; BTPAC, N = 69) and matched normal blood samples of Chinese PAC pts were detected and analyzed in a CAP&CLIA certified laboratory (OrigiMed company) with Yuansu panel including 450 genes. Total 100 males (65%) and 54 females (35%) with a mean age of 61 years old (yrs) were enrolled. We measured the somatic variations and calculated tumor mutational burden (TMB) after filtering known driver mutations (muts). Meanwhile, germline muts were analyzed among the tumor susceptibility genes. Fisher tests were used for comparative analyses.
Results
The median age in HPAC and BTPAC was 60 yrs and 62 yrs. Pts with stage 3&4 accounted for 40% and 60% in HPAC and BTPAC (P<0.05). Genomic alterations of KRAS and SMAD4 were significantly more prevalent in BTPAC (KRAS in BTPAC vs. HPAC= 97% vs. 82%, P=0.004; SMAD4 in BTPAC vs. HPAC= 42% vs. 21%, P=0.008). 2 NTRK3 fusions (3%) were found in BTPAC but 0 in HPAC. Additionally, muts frequency in Wnt pathway was 57% in BTPAC, whereas 37% in HPAC (P=0.02). No significant difference was found in TP53 (83% vs. 81%), CDKN2A (32% vs. 27%) and germline muts frequency (12% vs. 14%) between BTPAC and HPAC, nor in the mean TMB value (3.22 muts/Mb vs. 3.59 muts/Mb). For HPAC, there were more muts in HR pathway genes (24% vs. 19%), although the difference was not statistical significance. 2 BRCA2 germline muts were found in HPAC but neither BRCA1 nor BRCA2 was found in BTPAC.
Conclusions
Genomic pattern did not show apparent difference between the anatomic locations of PAC. However, we found more driver muts in KRAS and SMAD4 and more Wnt pathway muts related to proliferation and metastasis in BTPAC. Further research should be done to better understand the cancer biology among the locations and identify more therapy targets for precision medicine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5345 - Short-term Clinical Outcomes of Robotic-Assisted Total Mesorectal Excision in Rectal Cancer after concurrent chemoradiotherapy
Presenter: Pojung Chen
Session: Poster Display session 2
Resources:
Abstract
5489 - Local immune status in cancer cell nests can be a predictor of survival for rectal cancer with neoadjuvant radiotherapy
Presenter: xijin lin
Session: Poster Display session 2
Resources:
Abstract
1653 - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.
Presenter: Clémence Brun
Session: Poster Display session 2
Resources:
Abstract
5206 - Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer.
Presenter: Per Pfeiffer
Session: Poster Display session 2
Resources:
Abstract
2992 - Clinical impact of mucinous and poorly differentiated tumors on the outcome of patients with stage II colon cancer: a TOSCA subgroup analysis
Presenter: Gerardo Rosati
Session: Poster Display session 2
Resources:
Abstract
4753 - Exercise improved adjuvant treatment completion rates and treatment-related toxicities in colorectal cancer: A prospective pilot study
Presenter: Hong Jun Kim
Session: Poster Display session 2
Resources:
Abstract
2735 - Bevacizumab plus Oxaliplatin-Based Chemotherapy as Adjuvant Treatment for Colon Cancer (CC): Updated analysis of stage II disease from the AVANT Phase III Randomized trial by the GERCOR Group
Presenter: Aimery De Gramont
Session: Poster Display session 2
Resources:
Abstract
1843 - Multicenter Validation of the Postoperative Carcinoembryonic Antigen Combined Prognostic Model for Stage Ⅲ Colon Cancer
Presenter: Ji Zhu
Session: Poster Display session 2
Resources:
Abstract
2554 - Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey.
Presenter: Kaissa Ouali
Session: Poster Display session 2
Resources:
Abstract
3285 - Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer
Presenter: Philip Falk
Session: Poster Display session 2
Resources:
Abstract